PDS Biotechnology Total Liabilities 2014-2024 | PDSB

PDS Biotechnology total liabilities from 2014 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

PDS Biotechnology Total Liabilities 2014-2024 | PDSB

PDS Biotechnology total liabilities from 2014 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$145.5B
Vertex Pharmaceuticals (VRTX)$119.4B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$113.1B
CSL (CSLLY)$84.9B
Regeneron Pharmaceuticals (REGN)$80.4B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.7B
Alnylam Pharmaceuticals (ALNY)$31.7B
BioNTech SE (BNTX)$28.6B
Illumina (ILMN)$22.8B
Biogen (BIIB)$21.9B
BeiGene (BGNE)$17.5B
Moderna (MRNA)$16.1B
Genmab (GMAB)$13.3B
Incyte (INCY)$13.2B
Insmed (INSM)$12.8B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12B
Sarepta Therapeutics (SRPT)$11.8B
Exact Sciences (EXAS)$11.3B
Vaxcyte (PCVX)$10.9B
QIAGEN (QGEN)$10.4B
Exelixis (EXEL)$10B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$8.8B
Repligen (RGEN)$8.8B
Roivant Sciences (ROIV)$8.6B
Ascendis Pharma (ASND)$7.9B
Revolution Medicines (RVMD)$7.6B